This study is the first to investigate the role of ITGA2 in chronic myeloid leukemia (CML), with a particular focus on imatinib (IMA)-resistant CML. This evidence concerns the gene ITGA2 and chronic myelogenous leukemia, BCR-ABL1 positive.